Analysts think ALT stock price could increase by 492%
Aug 10, 2025, 11:25 AM
9.43%
What does ALT do
Altimmune, a clinical-stage biopharmaceutical company in Gaithersburg, Maryland, develops peptide-based therapeutics for obesity and liver diseases, including the lead candidate pemvidutide. The company has completed Phase II trials for both pemvidutide and HepTcell, targeting metabolic dysfunction and hepatitis B.
10 analysts think ALT stock price will increase by 492.16%. The current median analyst target is $20.40 compared to a current stock price of $3.44. The lowest analysts target is $1.01 and the highest analyst target is $29.40.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
